XBIT XBiotech Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1626878 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-49.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-29.9%
ROA-29.0%
ROIC (approx.)-193.7%
Asset turnover—
Leverage & solvency
Liabilities / assets3.5%
Debt / equity0.00x
Current ratio39.51x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.94x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $4.66M | $5.30M | $5.21M | $25.36M | $5.08M | $5.34M | $11.62M | $7.82M |
| SG&A expense | $663,000 | $850,000 | $1.07M | $4.40M | $967,000 | $1.00M | $1.93M | $927,000 |
| Operating income | -$5.32M | -$6.15M | -$6.27M | -$29.75M | -$6.05M | -$6.34M | -$13.55M | -$8.75M |
| Pretax income | -$4.42M | -$6.68M | -$5.46M | -$26.82M | -$5.91M | -$1.73M | -$10.86M | -$10.55M |
| Income tax | $35,000 | $46,000 | $49,000 | $76,000 | $102,000 | $28,000 | $29,000 | -$41,000 |
| Net income | -$4.46M | -$6.73M | -$5.50M | -$26.89M | -$6.01M | -$1.76M | -$10.88M | -$10.51M |
| EBITDA | -$5.07M | -$5.84M | -$5.94M | -$29.38M | -$5.62M | -$5.90M | -$13.11M | -$8.31M |
| EPS (basic) | -0.15 | -0.22 | -0.18 | — | -0.20 | -0.06 | -0.36 | — |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $105.04M | $109.53M | $115.46M | $125.55M | $147.37M | $152.94M | $155.90M | $172.68M |
| Receivables | — | — | — | — | $450,000 | $480,000 | $480,000 | $700,000 |
| Current assets | $106.36M | $111.16M | $117.05M | $126.95M | $148.95M | $154.89M | $157.69M | $174.57M |
| PP&E, net | $22.25M | $22.49M | $22.79M | $23.13M | $23.47M | $23.79M | $24.18M | $24.53M |
| Total assets | $128.61M | $133.65M | $139.84M | $150.08M | $172.42M | $178.68M | $181.86M | $199.09M |
| Current liabilities | $2.69M | $3.35M | $3.00M | $7.93M | $3.56M | $3.86M | $5.41M | $15.11M |
| Total liabilities | $4.55M | $5.19M | $4.82M | $9.73M | $5.34M | $5.62M | $7.15M | $16.82M |
| Shareholders' equity | $124.06M | $128.46M | $135.02M | $140.35M | $167.08M | $173.06M | $174.71M | $182.27M |
| Shares outstanding | 30.49M | 30.49M | 30.49M | 30.49M | 30.49M | 30.49M | 30.49M | 30.49M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.52M | -$4.51M | -$8.97M | -$22.95M | -$4.26M | -$5.99M | -$6.72M | -$6.54M |
| Capital expenditure | $12,000 | $0 | $0 | $34,000 | $110,000 | $51,000 | $94,000 | $84,000 |
| Free cash flow | -$4.53M | -$4.51M | -$8.97M | -$22.99M | -$4.37M | -$6.04M | -$6.81M | -$6.62M |
| Investing cash flow | -$17,000 | -$4,000 | $9,000 | -$34,000 | -$110,000 | -$51,000 | -$94,000 | -$84,000 |
| Financing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | -$10.25M | $283,000 |
| Depreciation & amortization | $252,000 | $302,000 | $332,000 | $378,000 | $427,000 | $439,000 | $442,000 | $439,000 |
| Stock-based compensation | $64,000 | $172,000 | $172,000 | $162,000 | $24,000 | $107,000 | $3.33M | $628,000 |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.